Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
01/05/2024 | 23:00 | GlobeNewswire Inc. | Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
23/04/2024 | 14:30 | GlobeNewswire Inc. | Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
11/03/2024 | 22:57 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
05/03/2024 | 22:30 | GlobeNewswire Inc. | Tarsus to Participate at Upcoming Investor Conferences | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
05/03/2024 | 22:09 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
05/03/2024 | 14:30 | GlobeNewswire Inc. | Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
01/03/2024 | 23:17 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
01/03/2024 | 06:07 | GlobeNewswire Inc. | Tarsus Announces Pricing of $100.0 Million Public Offering | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
29/02/2024 | 22:37 | GlobeNewswire Inc. | Tarsus Announces Proposed $100.0 Million Public Offering | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
29/02/2024 | 22:32 | Edgar (US Regulatory) | Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
27/02/2024 | 22:22 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
27/02/2024 | 22:02 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
27/02/2024 | 12:00 | GlobeNewswire Inc. | Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
22/02/2024 | 14:00 | GlobeNewswire Inc. | Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
20/02/2024 | 23:00 | GlobeNewswire Inc. | Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
31/01/2024 | 23:00 | GlobeNewswire Inc. | Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
22/01/2024 | 23:05 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
27/12/2023 | 22:23 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
11/12/2023 | 14:00 | GlobeNewswire Inc. | Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
22/11/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
09/11/2023 | 22:18 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
09/11/2023 | 22:05 | GlobeNewswire Inc. | Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
09/11/2023 | 22:00 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
01/11/2023 | 23:35 | GlobeNewswire Inc. | Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
06/09/2023 | 14:00 | GlobeNewswire Inc. | Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
30/08/2023 | 22:30 | GlobeNewswire Inc. | Tarsus to Present at Upcoming Investor Conferences | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
24/08/2023 | 15:00 | GlobeNewswire Inc. | Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
10/08/2023 | 22:05 | GlobeNewswire Inc. | Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
02/08/2023 | 04:30 | GlobeNewswire Inc. | Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |
31/07/2023 | 22:29 | GlobeNewswire Inc. | Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock | NASDAQ:TARS | Tarsus Pharmaceuticals Inc |